Bayer vs Novartis: Kerendia, Roundup and a flat week

Bayer is still a two-headed trade. One head is pharmaceuticals, where the company can point to Kerendia and a pipeline that keeps producing incremental wins. The other is litigation and agriculture, where the Roundup file keeps pulling attention back to cash, liability, and the cost of simply getting through the year. Novartis, by contrast, gives you a much cleaner read. You can argue about valuation, pipeline durability, and the usual patent math, but you do not have to price in the same kind of legal drag.

The stock sat in a narrow band around €48 in the final sessions of the week ending September 21. On September 18 it closed at €48.09 after a 1.94% decline, and on September 21 intraday trading was near €48.74 with modest gains in real-time feeds. A 2.3% drop to €47.96 was also reported on September 19 during a DAX-wide sell-off. The market was not ignoring Bayer. It was weighing it.

Our cohort data for this role-and-size bucket shows a historical T+90 return of -0.4%, which is a useful check on enthusiasm and nothing more. It is a historical bucket read, not a forecast for this name, and it sits in the same frame as the stock's own mixed tape, where one good regulatory headline has to compete with a much larger legal bill.

Kerendia expands Bayer's pharma case, Novartis remains the benchmark

The cleanest company-specific catalyst was the FDA's expanded indication for Kerendia, Bayer's finerenone franchise, in adults with chronic kidney disease associated with type 1 diabetes. That matters because it broadens the drug's addressable market in a high-unmet-need area, and it does so in a part of the portfolio that the market can actually model. This is not a vague pipeline promise. It is a label expansion on an existing asset.

Novartis is the right comparison because it shows what a more straightforward pharma rerating looks like. The Swiss group has been one of the sector's steadier references as European regulators kept a busy approval cycle in motion, with the CHMP issuing positive opinions on September 18 for multiple new medicines and label expansions from peers including AstraZeneca and Novo Nordisk. In that context, Bayer's Kerendia update fits the broader theme of established assets getting more life through incremental indications. The difference is that Novartis does not have to carry the same legal ballast while it does it.

Bayer also has the agriculture side of the house, and that matters when you compare it with a pure pharma name like Novartis. Crop science gives Bayer exposure to a different cycle, one that can help when pharma is quiet and hurt when input demand or pricing weakens. The company has also advanced biofuel-related partnerships, which ties it to a demand-cycle theme that is real enough, but not yet the kind of thing that changes the stock on its own. Novartis does not have that complication. Bayer does.

The result is a valuation argument that never stays still for long. A label expansion should support the case for the pharma franchise. It does not erase the fact that the market still has to discount litigation and a more complicated earnings mix. That is the gap between Bayer and Novartis, and it is why the same week can produce a positive drug headline and a stock that still looks pinned to a narrow range.

Roundup still owns the cash-flow conversation

The other side of the ledger is the Missouri court hearing tied to Bayer's proposed $7.25 billion Roundup settlement. That file has been around long enough that the market knows the shape of the risk, but not long enough to stop caring about it. Every new hearing, every procedural turn, every reminder that the settlement still needs to survive legal scrutiny keeps the cash-flow question alive.

This is where the comparison with Novartis gets useful again. Novartis can miss on a trial read or face a patent issue, but it is not carrying a litigation overhang of this scale. Bayer is. That difference matters when you are trying to decide whether a move in the stock is a rerating or just a reaction to the latest headline. The market can reward Kerendia and still refuse to pay up for the whole company because the Roundup file keeps sitting on the other side of the table.

The broader market backdrop did Bayer no favors either. The DAX traded near 25,300 to 25,580 points in the September 18 to 21 window, with modest weekly volatility and a year-to-date advance of roughly 3% to 4% for the index. Bayer has outperformed the broader German market on a year-to-date basis, helped by pipeline momentum and earlier financing steps such as the Apollo equity investment, but litigation-related cash outflows remain a drag on free cash flow. That is the kind of sentence that sounds obvious until you try to put a multiple on it. Then it gets expensive fast.

The stock's own action reflected that tension. A 1.94% drop on September 18, a 2.3% fall on September 19, then a move back toward €48.74 intraday on September 21 is not a clean trend. It is a market trying to decide whether the drug news deserves more weight than the legal noise. So far, it has not decided.

The activist block sale says something about patience

The insider or holder action that mattered most was not a classic management buy. It was the block sale by Inclusive Capital Partners, the activist firm linked to Jeff Ubben, of approximately 8.5 million shares, roughly 0.9% of Bayer, for about EUR 378 million to EUR 380 million in euro-normalised filing value. That is a large piece of stock to put into the market, and it briefly pressured the shares.

The point is not to overread the motive. Activists trim for all kinds of reasons, and a sale does not automatically mean the thesis is broken. But the size matters. A holder with a public campaign history is not usually the kind of seller that the market can ignore, especially in a name already carrying litigation overhang and a mixed operating story. If you want a simple read, this was supply hitting a stock that did not need more supply.

Against Novartis, the contrast is sharp. Novartis tends to be judged on execution, pipeline, and capital allocation. Bayer has to be judged on those things and on whether large holders still want to keep exposure through a legal process that can move slowly and cost real money. That is why the block sale landed as more than a footnote. It told you that at least one large, informed holder was willing to reduce exposure even as the company was getting a positive pharma headline.

Our scoring does not turn that into a grand verdict. It simply treats the filing as one more piece of evidence in a name where the market already knows the story is complicated. The signal sits in the context, not in the transaction alone.

How the cohort bucket frames the filing

The historical cohort read is useful precisely because it is modest. A -0.4% T+90 return does not hand you a bullish story to sell. It tells you that this bucket, on average, has not delivered much follow-through over the next 90 days. That is a better discipline than pretending every large filing is a hidden edge.

For Bayer, that matters because the company already has enough moving parts. You do not need to force a heroic interpretation onto a block sale when the stock is already being pulled in opposite directions by Kerendia, Roundup, and the broader European market. The cohort number keeps the analysis honest. It says the filing is worth reading, not worshipping.

It also keeps the comparison with Novartis grounded. If you were looking at a cleaner pharma name with a more straightforward operating profile, you might be more willing to let a single insider or holder action carry weight. Bayer is not that name. The legal overhang, the crop science exposure, and the activist history all make the stock more sensitive to context than to any one transaction.

Scale, valuation, and why the comparison still matters

Bayer's scale is part of the problem and part of the opportunity. Large diversified healthcare and agriculture groups can absorb shocks better than smaller names, but they also take longer to rerate when one part of the business is under a cloud. That is why the stock can trade near €48 even after a meaningful pharma win. The market is not paying for the headline alone. It is pricing the whole machine, including the parts that do not cooperate.

Novartis is the cleaner valuation reference because it gives you a benchmark for what the market will pay when the legal noise is absent and the operating story is more legible. Bayer can point to the same sector tailwinds, the same European approval cycle, and the same appetite for incremental label expansions. It still trades at a discount in spirit because the Roundup file keeps the discount alive. That is the gap you are really looking at.

The broader sector backdrop helps explain why the stock did not collapse on the legal headlines and did not rip on the Kerendia news. European pharma has been busy, with CHMP opinions supporting a range of new medicines and label expansions. Sanofi has been pushing innovation over older assets, AstraZeneca and Novo Nordisk have been collecting positive opinions, and the market is rewarding selective strength in late-stage or already-commercialized drugs. Bayer fits that pattern on the pharma side. It just does not get to stop there.

If you are comparing Bayer with Novartis, the question is not whether Bayer has assets worth owning. It does. The question is whether the market will pay for those assets while the legal and capital structure story remains unresolved. Right now the answer looks like a cautious no, or at least a not yet.

What to watch while the stock stays near €48

The next thing to watch is whether Kerendia's expanded indication starts to show up in how the market talks about the pharma franchise. A label expansion is only the first step. The market will want to see whether management can turn it into a cleaner earnings narrative, especially when the rest of the company is still carrying baggage.

The second thing is the Roundup process in Missouri. That is the file that can change the tone fastest, because it reaches directly into cash flow and legal risk. If the settlement path gets clearer, Bayer gets room to argue for a higher multiple. If it does not, the stock can keep drifting in a narrow band even when the pharma side does something right.

The third is holder behavior. The Inclusive Capital sale was large enough to matter, and it is a reminder that activist patience is not infinite. If more supply comes from large holders, the stock will have to absorb it against a backdrop that is still only partly constructive. If the selling stops and the company keeps delivering incremental pharma progress, the comparison with Novartis gets a little less punishing.

For now, the market is telling you that Bayer is still a story of offsets. One side of the company got a real regulatory win. The other side still has a legal bill attached. The stock around €48 reflects that balance, and the next move will probably come from whichever side changes first.

This is not investment advice.